Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone mineralization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Bone mineralization. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-002692-42 Sponsor Protocol Number: 1.1_2011 Start Date*: 2012-06-20
    Sponsor Name:MUW-Medical University of Vienna,Medizinische Universität Wien
    Full Title: Characterization of myeloma bone lesions - before and during anti-cancer therapy - using 18F-FDG-, 18F-fluoride PET/CT and MRI- a pilot study
    Medical condition: The primary aim of this study is the characterization of WB MRI detected untreated MM bone lesions in consideration of the mineralization status and tumor activity using 18F-fluorid-PET/CT and 18F ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006692-20 Sponsor Protocol Number: independant Trial (TOMIBA-TRIAL01) Start Date*: 2007-09-06
    Sponsor Name:St. Vincent Hospital, Medical Department II
    Full Title: The TOMIBA study Treatment of Osteoporotic Men With Intravenous Ibandronate An open-label, single-center, prospective Phase III study
    Medical condition: Osteoporosis in Men
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000515-95 Sponsor Protocol Number: B3D-EW-GHCX Start Date*: 2005-06-16
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study
    Medical condition: Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004778-99 Sponsor Protocol Number: 120895 Start Date*: 2005-06-14
    Sponsor Name:Pediatric Unit, Hillerød Hospital
    Full Title: The growth of the internal genitalia and the bone mineralization during hormonal replacement therapy and the presence of aortic root dilatation in girls with Turner Syndrome
    Medical condition: Turner Syndrome is a common chromosomal abnormalities, characterized by one X-chromosome or a partial deletion in all or some cell-lines. The syndrome is known for features as short stature and abs...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018543-34 Sponsor Protocol Number: 12153599 Start Date*: 2010-06-11
    Sponsor Name:Orthopaedic Syrgery Unit Northern Jytland
    Full Title: NSAIDs INFLUENCE ON HEAL OF COLLES FRACTURE
    Medical condition: Ivestigations hypotheses: 1. NSAIDs provide a significant postoperative pain relief that can make mobilization / rehabilitation faster and easier oedema prophylaxis. 2. NSAIDs do not affect bone he...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009924 Colles' fracture LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000995-18 Sponsor Protocol Number: IGG-MOMA-001 Start Date*: 2007-06-25
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: EFFICACY AND TOLERABILITY OF TWO REPLACEMENT THERAPIES FOR AMENORRHEA IN CHILDREN TREATED FOR CANCER
    Medical condition: primary and secundary amenorrhea
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001928 Amenorrhoea LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024013-31 Sponsor Protocol Number: CBPS804A2202 Start Date*: 2011-06-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of multiple infusions of BPS804 in adults wit...
    Medical condition: Hypophosphatasia (HPP) is a rare genetic metabolic disorder which results in impaired skeletal mineralization, and which is caused by the absence of or by deficient enzymatic activity of the tissue...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005581-39 Sponsor Protocol Number: CL3-12911-025 Start Date*: 2007-04-02
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bo...
    Medical condition: Treatment of postmenopausal Osteoporosis to reduce the risk of hip and vertebral fractures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) IT (Completed) DK (Completed) EE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004643-53 Sponsor Protocol Number: 20050104 Start Date*: 2006-03-14
    Sponsor Name:Amgen Inc.
    Full Title: Bone Histomorphometry Assessment For Incident Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease. Valoración ósea histomorfométrica en pacientes incidentes en diálisis...
    Medical condition: Secondary hyperparathyroidism (HPT) in subjects with CKD receiving dialysis. Hiperparatiroidismo (HPT) secundario en sujetos con IRC tratados con Diálisis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) CZ (Completed) PT (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002118-21 Sponsor Protocol Number: CPZOL Start Date*: 2017-03-17
    Sponsor Name:Randers Regional Hospital
    Full Title: Zoledronate against fractures in children with cerebral palsy
    Medical condition: cerebral palsy, osteopenia, fracture
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10049088 Osteopenia PT
    15.1 100000005035 10034157 Pathological fractures and complications HLT
    20.0 10042613 - Surgical and medical procedures 10049904 Osteoporosis prophylaxis PT
    20.0 100000012650 10021740 Infantile cerebral palsy LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10006002 Bone pain PT
    20.0 100000018618 10013522 Disuse osteoporosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-004946-41 Sponsor Protocol Number: SP-PP18 Start Date*: 2019-09-12
    Sponsor Name:Dr. Virgilio P. Carnielli,
    Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial
    Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition.
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004105-32 Sponsor Protocol Number: 307-MET-9002-052 Start Date*: 2015-04-01
    Sponsor Name:Pfizer Inc
    Full Title: Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor (Genotonorm) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-Term Corticosteroid T...
    Medical condition: Juvenile idiopathic arthritis (JIA)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001775-41 Sponsor Protocol Number: UX023-CL304 Start Date*: 2015-12-16
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phospha...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001983-49 Sponsor Protocol Number: UX023-CL205 Start Date*: 2019-10-10
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children from 1 to 4 Years Old with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phosphat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004840-21 Sponsor Protocol Number: RISED_C_00935 Start Date*: 2007-04-23
    Sponsor Name:sanofi-aventis Netherlands B.V.
    Full Title: Bone Histomorphometry, Microarchitecture and Matrix Structure and Properties in Patients Receiving Long-term Risedronate Treatment
    Medical condition: The objective of this study is to collect data on bone histomorphometry, architecture, turnover and material properties from iliac crest biopsies taken from postmenopausal women after > 5 year rise...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001552-19 Sponsor Protocol Number: TOPMATEPY4067 Start Date*: 2014-12-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects ...
    Medical condition: New-onset or recent-onset epilepsy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) HU (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002477-59 Sponsor Protocol Number: CDGP1 Start Date*: 2012-12-12
    Sponsor Name:Taneli Raivio, Helsingin yliopistollinen keskussairaala
    Full Title: Constitutional Delay of Growth and Puberty: towards evidence-based treatment
    Medical condition: constitutional delay of puberty
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10012205 Delayed puberty PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004104-30 Sponsor Protocol Number: 307-MET-9002-0009 Start Date*: 2015-04-01
    Sponsor Name:Pharmacia & Upjohn S.A.
    Full Title: Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety
    Medical condition: Juvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004984-11 Sponsor Protocol Number: P150962J Start Date*: 2018-07-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: "Study of maintenance of the efficacy and adverse effects of pharmacological treatments in sex offenders with paraphilia" ESPARA
    Medical condition: Sexual offenders with paraphilia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10033888 Paraphilia PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004940-48 Sponsor Protocol Number: 2013-004940-48 Start Date*: 2014-11-12
    Sponsor Name:Danderyds Hospital, Department of Clinical Sciences, Division of Orthopaedics
    Full Title: Denosumab For Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty. A randomized, double-blind, placebo-controlled trial using volumetric computed tomography.
    Medical condition: Patients with titanium press-fit acetabular components with polyethylene liners will be screened for osteolytic lesions. The patients had primary surgery at least 7 years before screening and all o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 19:02:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA